Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
Conclusion Results from the PRISM Phase 3 program support the efficacy of pegvaliase for the treatment of adults with PKU, with a manageable safety profile in most participants. The PRISM-2 extension study will continue to assess the long-term effects of pegvaliase treatment.
Source: Molecular Genetics and Metabolism - Category: Genetics & Stem Cells Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Brain | Clinical Trials | Food Allergy | Genetics | Headache | Infectious Diseases | Migraine | Neurology | Phenylketonuria | Study